Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Managing multiple myeloma (MM) patients undergoing advanced treatment lines (four or more) presents significant clinical challenges.
• Real-world data (RWD) are crucial for understanding the unmet medical needs of this complex patient population.

Purpose of the Study:

• To describe the characteristics and outcomes of MM patients receiving advanced-line treatments using RWD.
• To evaluate treatment patterns and patient survival in a real-world setting for heavily pretreated MM.

Main Methods:

• Analysis of the EMMY cohort, a French longitudinal RWD study.
• Inclusion of 2127 MM patients treated between 2017 and 2020 with four or more lines of therapy.
• Description of patient characteristics, treatment variations, time to next treatment, and overall survival.

Main Results:

• A wide range of treatments were utilized without a dominant combination, indicating evolving therapeutic strategies.
• Median time to next treatment decreased from 7.8 months in Line 4 to 4.8 months in Line 8.
• Median overall survival declined from 19.4 months in Line 4 to 12.6 months in Line 8, indicating poor outcomes.

Conclusions:

• The EMMY study reveals rapid disease progression and suboptimal outcomes in advanced MM patients prior to the widespread availability of novel anti-BCMA therapies.
• These findings underscore the critical need for the development and implementation of innovative therapeutic options for patients with refractory multiple myeloma.